8-K: Connect Biopharma Initiates Phase 2 COPD Study Following FDA Agreement

Connect Biopharma has commenced a Phase 2 clinical trial to assess rademikibart as a treatment for acute exacerbations of chronic obstructive pulmonary disease (COPD).

Summary

• Connect Biopharma has initiated a Phase 2 clinical trial, named Seabreeze STAT COPD study, to evaluate the safety and efficacy of rademikibart in treating acute exacerbations of COPD.
• The study follows a written agreement on the final study protocol from the FDA.
• The trial will enroll approximately 160 participants globally with COPD and type 2 inflammation, characterized by an eosinophil count of 300 cells/L.
• Participants will receive a single subcutaneous dose of either rademikibart or a placebo, in addition to standard care.
• The primary endpoint is the treatment failure rate over 28 days following an acute exacerbation.
• Secondary endpoints include the rate and time to new moderate and severe COPD exacerbations, changes in respiratory symptoms, FEV1, and adverse event incidence.
• Topline data from the study is expected in the first half of 2026.
• Rademikibart is a next-generation anti-IL-4R antibody being developed for both asthma and COPD.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the initiation of a Phase 2 trial and the potential of rademikibart to address an unmet need in COPD treatment. However, the inherent risks associated with drug development temper the overall sentiment.

Positives

• The FDA has agreed to the final study protocol, allowing the Phase 2 trial to proceed.
• Rademikibart has shown promise in previous trials for asthma, suggesting potential efficacy for COPD.
• The study addresses a significant unmet need for fast, effective treatments following acute COPD exacerbations, where current options are limited.
• The company plans to present data from a post-hoc analysis of a previous asthma study at the upcoming American Thoracic Society (ATS) 2025 International Conference.

Risks

• The forward-looking statements include risks related to clinical trial outcomes, regulatory approvals, and market acceptance.
• Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product.
• Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

Future Outlook

Connect Biopharma expects to report topline data from the Seabreeze STAT COPD study in the first half of 2026 and is focused on advancing the development of rademikibart for asthma and COPD.

Management Comments

• Barry Quart, Pharm.D., CEO and Director of Connect Biopharma, stated that the initiation of the Phase 2 study highlights the company's commitment to advancing rademikibart for asthma and COPD.
• Surya Bhatt, MD, Professor of Medicine at the University of Alabama at Birmingham School of Medicine, is excited to participate in the Seabreeze STAT COPD study to evaluate if rademikibart can deliver rapid, lasting relief for patients.

Industry Context

The announcement addresses the unmet need for effective treatments for acute exacerbations of COPD, a significant issue given the high number of emergency department visits and treatment failures. The company believes rademikibart holds the potential to be the first biologic to rapidly improve lung function and prevent further exacerbations over the shortand long-term.

Comparison to Industry Standards

• Currently, there are no approved biologics that can rapidly improve lung function and prevent further exacerbations over the shortand long-term in patients experiencing an acute exacerbation with asthma or COPD.
• Rademikibart is being compared to existing standard of care treatments for COPD exacerbations, such as bronchodilators and corticosteroids, with the aim of demonstrating superior efficacy and safety.
• Companies like AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim offer treatments for COPD, but Connect Biopharma aims to differentiate rademikibart by targeting type 2 inflammation and providing rapid relief.

Stakeholder Impact

• Positive impact on patients with COPD by potentially providing a new treatment option for acute exacerbations.
• Potential benefit to shareholders if the clinical trial is successful and rademikibart is approved for marketing.
• Positive impact on the company's reputation and market position in the biopharmaceutical industry.

Next Steps

• Enrollment of approximately 160 participants in the Phase 2 Seabreeze STAT COPD study.
• Data presentation at the American Thoracic Society (ATS) 2025 International Conference.
• Reporting topline data from the Seabreeze STAT COPD study in the first half of 2026.

Key Dates

Keywords

rademikibart, COPD, Connect Biopharma, clinical trial, Phase 2, acute exacerbations, FDA, asthma, IL-4R antibody